Japan’s FY26 price revision expands G1 repricing and drives price reduction
Japan’s latest National Health Insurance (NHI) drug price revision for FY26 has now come into effect, with an average 4.02%…
All articles by Simran Gurung
Simran Gurung
-
-
The Most Favored Nation Policy: early insights into Europe’s response
On 12 May 2025, US President Donald Trump signed an executive order directing the US Department of Health and Human…
-
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
Orphan drugs are therapeutics developed to address rare diseases typically defined by patient population thresholds that vary across regions: fewer…
-
5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
To assess the impact of pharmaceutical policy and market dynamics on market access, GlobalData has conducted a comparative analysis of…